Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) Derivative Liability, Fair Value, Gross Liability

2.8 / 5 stars · 68/120 Roast Me

AMARIN CORP PLC\UK Derivative Liability, Fair Value, Gross Liability

AMARIN CORP PLC\UK (AMRN) had Derivative Liability, Fair Value, Gross Liability of $7.20 million as of 2013-09-30, per its 10-Q filed 2013-11-07.

Discontinued › Notes

us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2013-11-07

  • 2013-09-30: Derivative Liability, Fair Value, Gross Liability $7.20M.
  • 2013-06-30: Derivative Liability, Fair Value, Gross Liability $8.60M.
  • 2013-03-31: Derivative Liability, Fair Value, Gross Liability $15.60M.
Period endDerivative Liability, Fair Value, Gross Liability
2013-09-30$7.20M
10-Q · filed 2013-11-07
2013-06-30$8.60M
10-Q · filed 2013-08-08
2013-03-31$15.60M
10-Q · filed 2013-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B